Boston Scientific reveals a trifecta of reimbursement wins for its S-ICD, including a new reimbursement code from the AMA, a 23% increase in the Medicare rate for implantation and an expansion of coverage by private insurer Aetna.
Boston Scientific (NYSE:BSX) yesterday revealed a trifecta of reimbursement wins for its S-ICD subcutaneous defibrillator from the American Medical Assn., Medicare and Aetna.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1zVmxkW
Cap comentari:
Publica un comentari a l'entrada